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CD4+ helper T cells are indispensible in shaping the
adaptive immune system and play an important role in
protection against infections. The establishment of a wide
range of long-lived pathogen-speciﬁc T cells, which are
ready-to-act upon second encounter with the speciﬁc path-
ogen, is a fundamental property of the adaptive immune
response. However, the mechanisms by which antigen
speciﬁc helper T are sustained long-term and resist insult by
lymphocytotoxic agents is not well deﬁned. A recent report
described the existence of a long-lived CD8+ memory T cell
population with stem cell-like properties (Turtle et al.,
Immunity 2009) including the ability to efﬂux cellular toxins
through the ATP-binding cassette (ABC)esuperfamily
multidrug efﬂux protein ABCB1. We hypothesized that
a subset of memory T cells with stem-like properties also
exists within the CD4+ T cell compartment.
Here we identiﬁed a subset of memory CD4+ T cells with
rapid drug-efﬂuxing ability. We showed that drug efﬂuxing
CD4+T cells have a remarkable phenotypic similarity to CD8+
stem-like memory T cells described by Turtle et al and are
deﬁned as CD161+CD95+CD45RA-CD127hiCD28+CD25int.
Furthermore, efﬂuxing CD4+CD161+ T cells proliferated
poorly in response to anti-CD3/CD28 stimulation compared
to their CD161- counterpart, indicating that this subset of
quiescent T cells may resist insult by cytotoxic agents
through a number of different mechanisms.
We demonstrated that CD4+CD161+ T cells are enriched
within the viral-speciﬁc T cell repertoire and persist after
chemotherapy for AML. The high ABCB1-mediated drug
efﬂux capacity of CD4+ CD161+ memory cells facilitated their
resistance to daunorubicin in vitro and, this resistance was
abrogated by the addition of competitive inhibitors of ABCB1
and ABCC1. Finally we demonstrated that following vacci-
nation with seasonal inﬂuenza vaccine (Flu), CD161 expres-
sion was signiﬁcantly higher on Flu-speciﬁc CD4+ T cells at 2
years, compared to 4 weeks post-vaccination, (74.3%  4.6%
vs. 49.3%  3.5% P  .007), suggesting that CD161 is a marker
for long-lived Ag speciﬁc memory T cells. These data have
signiﬁcant implications for the development of novel adop-
tive therapy strategies using long-lived stem-like memory T
cells.
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Autologous stem cell transplantation (auto-SCT) is
uncommonly associated with acute graft-versus-host
disease (aGVHD)-like syndromes that are typically mild and
self-limited; incidence is increased when auto-SCT is
coupled with infusion of ex vivo expanded/costimulated T-
cells. We describe here a gastrointestinal GVHD-like
syndrome in multiple myeloma (MM) patients treated with
auto-SCT and T-regulatory-cell (Treg)-depleted, autologous T-
cells genetically modiﬁed to express a T-cell receptor with
engineered speciﬁcity for a HLA-A*02-restricted epitope
common to cancer-testis antigens NY-ESO-1 and LAGE-1.
Subjects were HLA-A2+ and had high-risk MM with
conﬁrmed target expression. After initial therapy, T-cells
were harvested via apheresis for transduction and culture
with anti-CD3/-CD28-antibody-conjugated microbeads.
Stem cells were then mobilized with cyclophosphamide +/-
bortezomib. Subjects received melphalan 200 mg/m2 on day
-2 and >2 x 106 CD34+ cells/kg on day 0. On day +2, autol-
ogous T-cells were infused (avg. 9x109, range 7-10x109;
gene-modiﬁed avg. 33%, range 18-38%). Of the ﬁrst 3 subjects
treated, all developed persistent fever and grade 3-4 diarrhea
beginning between days 2-7. Abdominal imaging was ob-
tained in 2 subjects and demonstrated marked wall thick-
ening in the small and large bowel. Bowel biopsies from all
subjects demonstrated aGVHD. The syndrome resolved
spontaneously on day +37 in subject #1, but subjects #2 and
#3 required immunosuppression with steroids. With recog-
nition of this syndrome, prophylactic administration of oral
budesonide and beclomethasone was implemented. The
syndrome was then observed in only 1 of 7 subsequently
treated subjects; in this subject, symptoms developed only
after prophylactic budesonide was discontinued due to
inability to administer the drug while the subject was
ventilator-dependent with pneumonia. In subjects #2 and
#3, bowel biopsy specimens were assayed by qPCR for the
presence of the engineered cells, which were found to be
present in all biopsy specimens fromboth subjects. Q-RT-PCR
analysis of biopsy tissues showed absence of transcripts for
both NY-ESO-1 and LAGE-1 antigens and accumulation. In
conclusion, immunotherapy with Treg-depleted, NY-ESO-1/
LAGE-directed autologous T-cells after high-dose melphalan
is associated with a steroid-responsive and preventable
immune enteritis possibly mediated by inﬁltration of the GI
tract by the engineered autologous T-cells.46
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